Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs), designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/24 | $20,000,000 | Seed |
Alexandria Venture Investments Bison Ventures Breakout Ventures  GRIDS Capital Innovation Endeavors Wireframe Ventures | undisclosed |
